Lundbeck acquires Prexton to improve Parkinson’s treatment offering

Lundbeck is to acquire Prexton Therapeutics, in a move that will see it take control of promising Parkinson's disease treatment foliglurax.

Lundbeck is to pay EUR 100 million (GBP 87.6 million) upfront for Prexton, with further payments of up to EUR 805 million to its current owners relating to development and sales milestones.

Foliglurax is currently in clinical phase II testing for symptomatic treatment of off-time reduction in Parkinson's disease and dyskinesia. The drug targets motor symptoms of Parkinson's aiming to treat uncontrolled movements, tremors and muscle rigidity.

Interim CEO and CFO for Lundbeck Anders Götzsche described foliglurax as an "exciting first-in-class compound", adding it "addresses high unmet needs, with its potential indication in Parkinson's fitting perfectly within Lundbeck's core areas".

Based in Denmark, Lundbeck specialises in the development of treatments for psychiatric and neurological disorders, with a core focus on depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.